Squarepoint’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Squarepoint’s Portfolio DOVA Stock Details DOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-33,414	Closed	-$471K	–	2852
2019 Q2	$471K	Buy	+33,414	New	+$318K	﹤0.01%	1705
2019 Q1	–	Sell	-18,074	Closed	-$137K	–	2576
2018 Q4	$137K	Buy	+18,074	New	+$291K	﹤0.01%	1765
2018 Q3	–	Sell	-8,464	Closed	-$253K	–	2345
2018 Q2	$253K	Buy	+8,464	New	+$230K	﹤0.01%	1454

Other funds holding DOVA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's DOVA Position: Q3 2019 in Review

Squarepoint sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q3 2019, closing a stake of 33,414 shares — an estimated $471K sold.

Squarepoint first reported a position in DOVA in Q2 2018 and held it in 3 quarters. The position peaked at $471K in Q2 2019. 72 funds tracked by Wall St. Rank hold DOVA as of Q3 2019.

Squarepoint reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Squarepoint sold 33,414 Dova Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $471K.
Squarepoint first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 3 quarters.
Squarepoint's Dova Pharmaceuticals, Inc. Common Stock position peaked at $471K in Q2 2019.
72 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Squarepoint's 13F filing for Q3 2019, filed 14 Nov 2019.